Quest Diagnostics expands share repurchase program

Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that its Board of Directors increased the company's share repurchase authorization by $750 million.

"The expansion of our share repurchase program reflects the company's financial strength and our ability to continue generating strong cash flows, and, in addition to continuing to invest in the growth of our business, provides another means to return value to our shareholders," said Surya N. Mohapatra, Ph.D., Chairman and Chief Executive Officer.  

During 2009, the company repurchased approximately 10 million shares of common stock for $500 million, fully utilizing its previous authorization. The company had approximately 183 million shares outstanding as of December 31, 2009.

SOURCE Quest Diagnostics Incorporated

Posted in:

Tags: ,


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Quest Diagnostics. (2010, January 27). Quest Diagnostics expands share repurchase program. News-Medical. Retrieved on May 26, 2024 from

  • MLA

    Quest Diagnostics. "Quest Diagnostics expands share repurchase program". News-Medical. 26 May 2024. <>.

  • Chicago

    Quest Diagnostics. "Quest Diagnostics expands share repurchase program". News-Medical. (accessed May 26, 2024).

  • Harvard

    Quest Diagnostics. 2010. Quest Diagnostics expands share repurchase program. News-Medical, viewed 26 May 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Quest Diagnostics introduces digital cognitive assessment tool to help physicians assess patients with dementia